InflaRx (IFRX) Cash from Operations (2016 - 2026)
InflaRx's (IFRX) quarterly Cash from Operations came in at 8654555.75 in Q1 2026, up 41.3% year-on-year from 6125095.85 in Q1 2025, and down 58.0% quarter-over-quarter from 5477523.16 in Q4 2025.
InflaRx (IFRX) Cash from Operations (2016 - 2026) Analysis & Trends
InflaRx has disclosed Cash from Operations across 11 years of filings, most recently posting 8654555.75 for Q1 2026.
- Cash from Operations for Q1 2026 came in at 8654555.75, up 41.3% year-over-year; the trailing twelve-month figure through Mar 2026 was 33250090.41 (up 34.97% YoY), and the FY2025 annual result was 41107414.48, up 20.78% from the prior year.
- Cash from Operations came in at 8654555.75 for Q1 2026 at InflaRx, down from 5477523.16 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3192978.95 in Q3 2022 to a low of 16152422.19 in Q1 2024.
- The 5-year median for Cash from Operations is 11287469.73 (2023), against an average of 10452114.66.
- Across the five-year window, Cash from Operations jumped 72.82% in 2022 and sank 119.84% in 2023, its largest moves.
- InflaRx's Cash from Operations stood at 5322589.69 in 2022, then sank by 119.84% to 11701228.47 in 2023, then fell by 8.63% to 12710728.57 in 2024, then soared by 56.91% to 5477523.16 in 2025, then tumbled by 58.0% to 8654555.75 in 2026.
- The last three Cash from Operations figures came in at 8654555.75 (Q1 2026), 5477523.16 (Q4 2025), and 10568212.43 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.65 Mn |
| Mar 31, 2026 | -8.65 Mn |
| Dec 31, 2025 | -5.48 Mn |
| Dec 31, 2025 | -5.48 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Jun 30, 2025 | -8.55 Mn |
| Jun 30, 2025 | -8.55 Mn |
| Mar 31, 2025 | -14.74 Mn |
| Mar 31, 2025 | -14.74 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Sep 30, 2024 | -10.61 Mn |
| Sep 30, 2024 | -10.61 Mn |
| Jun 30, 2024 | -13.07 Mn |
| Jun 30, 2024 | -13.07 Mn |
| Mar 31, 2024 | -16.15 Mn |
| Mar 31, 2024 | -16.15 Mn |
| Dec 31, 2023 | -11.70 Mn |
| Dec 31, 2023 | -11.70 Mn |